CRO

Gene Therapy for Rare Disorders is dedicated to overcoming the unique drug development challenges encountered in transforming gene therapy concepts into reality for rare disease patients in need.As the gene therapy field strives to strike the balance between clinical efficacy and product safety in the context of mounting regulatory scrutiny, Gene Therapy for Rare Disorders provides in-depth insights from experts who know how to drive clinical progress, optimize manufacturing, and demonstrate the value of gene therapy products to regulators, payers, and patients.Across four days, this meeting will unite 500+ leading experts in Boston from innovative biotechs, large pharma, academia, and key service provider companies, delivering actionable insights and valuable networking opportunities to accelerate gene therapy progress.

The purpose of the CDISC Interchanges is to bring together those interested in improving medical research and accelerating the development of therapies for patients worldwide. At this event, we will discuss the successes, challenges, and opportunities for collaboration among stakeholders developing and implementing clinical research data standards and, through other means, streamlining the biomedical research process

Access new data & case studies from world-renowned speakers and companies across the entire landscape of oligonucleotides, peptides, mRNA, drug delivery and partnering strategies — from discovery to market, with an emphasis on the European region.Comprehensive CMC, analytical, manufacturing and regulatory strategies for both drug substance and drug product to accelerate oligonucleotide product development.Design oligonucleotides with better drug-like properties to accelerate your products to the clinic and to market. The latest preclinical and clinical updates to benchmark your research and improve your clinical efforts.

Industry leaders and service providers share cutting-edge content and company expertise across the oligonucleotide, peptide, MRNA and drug delivery spectrum.

Advance your innovative biologics pipeline and elevate your engineering, targets and machine learning strategies – accelerating your path to the clinic and beyond.

The Spring Clinical Meetings (SCM) is NKF’s premiere educational event designed for the interprofessional kidney health team. SCM presents a unique opportunity for busy renal health care professionals to explore innovation, research, and best clinical practice within nephrology.

Whether you are a clinical research novice or veteran, work with a study sponsor, research site or CRO, MAGI will offer best-in-class educational opportunities for all career levels in support of your continuing education and your professional growth and success.

Join clinical 800+ professionals at MAGI’s conference, which includes 100+ sessions and workshops in six tracks that offer practical information on clinical operations & project management, site management, contracts, budgets & billing, regulatory compliance, and special topics. About half of the attendees will have leadership roles like CEO, vice president, or director. About three-quarters will have eight or more years of clinical research experience. Study sponsors will be split about 75% biopharma and 25% medical device. Sites will be almost evenly split between (a) academic medical centers, (b) health systems and community hospitals, and (c) independent sites and clinics.

Interest in the field of health economics and outcomes research (HEOR) has grown exponentially as governments and other payers grapple with how to provide the best possible health outcomes at affordable costs. Renowned as the global Society that convenes all healthcare stakeholders in HEOR, ISPOR is leading the field at a time when solid approaches to decision making are more important than ever.

Join thousands of international thought leaders to discuss the latest research, technologies, innovation and business models in implementing precision medicine, biomarkers and companion diagnostics, genomic medicine, and precision health; innovation and market access strategies for at-home diagnostics, point-of-care testing and molecular diagnostics for infectious diseases; liquid biopsy and advanced diagnostics for precision oncology, including Multi-Cancer Early Detection and Minimal Residual Disease testing; and emerging technologies for spatial biology and single-cell multiomics.